Why Veru Stock Soared 15% Higher on Monday
Veru (NASDAQ: VERU), a somewhat under-the-radar coronavirus stock, landed on the radars on many investors at the start of the trading week. An analyst tapped the stock as one of his choice selections, and the market collectively responded by trading the biotech's shares nearly 15% higher on the day.
The attention Veru has gotten is due to sabizabulin, an experimental drug that treats Covid. Monday morning, Oppenheimer prognosticator Leland Gershell reiterated his bullish view on the stock, which he currently recommends as an outperform (i.e., buy) at a $36 per share price target.
Gershell's latest take on Veru is based on an interim analysis on sabizabulin published by the company last week.
Source Fool.com
